The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 08, 2022

Filed:

May. 09, 2018
Applicant:

Regeneran Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Amy Han, Hockessin, DE (US);

William Olson, Yorktown Heights, NY (US);

Assignee:

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 47/61 (2017.01); A61K 31/724 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 3/00 (2006.01); A61P 25/00 (2006.01); A61K 31/573 (2006.01); A61P 35/04 (2006.01); C07J 43/00 (2006.01); C07J 71/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6807 (2017.08); A61K 31/573 (2013.01); A61K 31/724 (2013.01); A61K 47/61 (2017.08); A61K 47/6803 (2017.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); A61P 3/00 (2018.01); A61P 25/00 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07J 43/003 (2013.01); C07J 71/0031 (2013.01);
Abstract

Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.


Find Patent Forward Citations

Loading…